In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb™

ArterioSorb™是一种创新的医疗植入物产品，目前正由英国医疗器械公司Arterius开发，用于治疗冠心病。冠心病是英国和世界范围内的主要死亡原因，每年在英国造成超过7.3万人死亡。ArterioSorb™是一种下一代可生物吸收的心血管支架(支架)，ArterioSorb™，植入冠状动脉内，以打开阻塞的血管，并在愈合完成后不再需要的两年内生物降解。在这个为期24个月的项目中，Arterius公司将进行必要的体外和体内研究，以证明ArterioSorb™的安全性和有效性。这项研究完成后，该公司将进入第一人试验和商业化，这将促进公司的增长和全球形象，创造新的技术性就业机会，并增强我们在支架技术领域的全球竞争力。目前还没有一家英国公司为全球市场提供BRS。在这个项目之后，ArterioSorb™将推出与全球BRS产品竞争的产品。Arterius的目标是发展成为在以聚合物为基础的BRS市场上具有全球竞争力的主要英国中小企业，用于治疗心血管疾病。

ArterioSorb™ is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaffold (BRS, stent), ArterioSorb™, to be implanted within the coronary arteries in order to open blocked vessels, and to biodegrade within two years when healing is complete and it is no longer needed. In this 24-month project, Arterius will perform the in-vitro and in-vivo studies necessary to demonstrate the safety and efficacy of ArterioSorb™. After completion of this study, the company will enter the First-in-Man trials and commercialisation, which will enhance the growth and global profile of the company, create new skilled jobs and enhance our global competitiveness in the field of stent technologies. There is currently no UK company offering a BRS for the global market. Following this project, ArterioSorb™ will launch to compete with the global BRS products. The goal of Arterius is to develop as a major UK SME with global competitiveness in the polymer based BRS market to treat cardiovascular disease.